Myriad Genetics delivered Q4 2025 revenues above analyst forecasts, driven by a notable increase in test volumes. The company also achieved improved gross margins compared with the prior year period, reflecting operational efficiencies and a favorable product mix.

During the earnings call, management reiterated its full-year 2026 revenue growth target and affirmed investment in commercial expansion. Executives pointed to broad adoption of its hereditary cancer panels and ongoing R&D initiatives as key catalysts for future growth.